Navigation Links
Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
Date:3/11/2010

FREMONT, Calif., March 11 /PRNewswire-FirstCall/ -- Vermillion, Inc (Pink Sheets: VRML) today announced that Gail Page, Vermillion's Chief Executive Officer, will be presenting at the Roth 22nd Annual OC Growth Stock Conference in Laguna Niguel.

The presentation is scheduled for Monday, March 15, 2010 at 2:00 p.m. Pacific.  The presentation will be web cast and is available through the investor relations section of our web site at www.vermillion.com.

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr)
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
2. Vermillion Announces the Reappointment of Officers and Confirmation of Director
3. Vermillion Announces $43.05 Million Private Placement of Common Stock
4. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
5. Vermillion Files Plan of Reorganization
6. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
7. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
8. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
9. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
10. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
11. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/18/2014)... being prepped to enter the battle against infectious ... diseases in remote areas, thanks in part to ... the International Space Station on the behavior of ... capillary flow to diagnose infectious diseases such as ... researcher at Northwestern University in Evanston, Ill., had ...
(Date:4/18/2014)... Three Johns Hopkins University School of Medicine researchers have ... treatments for diabetes, Novo Nordisk announced this month. Of ... Diabetes and Obesity Biologics Science Forum Program, only four ... Johns Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; ... , Jonathan Powell, a professor of oncology, will ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Researchers at Wake Forest University have uncovered evidence that the ... blood cell may be behind the development of lupus. Scientists ... to monitor patients response to therapy and possibly a new ... in the journal Immunology, involve an enzyme that edits and ...
... 19 Let,s be honest, with the,exception of Michael Jordan and ... off., You see so many hair loss treatments advertised on ... this was in fact,the case, then no one would be bald. ... fellow colleagues, the more you see that hair loss is,on the ...
... involved in deciding how to treat coronary artery disease, ... complications. Some studies have found that cognitive decline and ... coronary artery bypass surgery. A new study finds no ... long-term cognitive decline than patients not undergoing surgery. The ...
... 19, 2008 NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today ... annual Digestive Disease Week (DDW) Congress on GATTEX (teduglutide), ... parenteral nutrition (PN) in patients with intestinal failure ... The Phase 3 study evaluated two doses of GATTEX ...
... Comparison Tool Gives Anthem Members in six California, counties - Los ... Most Complete Picture of Costs Associated with Medical ... ... Cross in,California announced today the expansion of its industry-leading,transparency initiative into California. ...
... tests to guide lung cancer treatment has taken a ... ability of five high-risk genetic profiles, or signatures, to ... whose non-small cell lung cancer was caught early and ... American Thoracic Societys 2008 International Conference in Toronto on ...
Cached Medicine News:Health News:Abnormal 'editing' of gene messages may be a cause of lupus 2Health News:New Hair Loss Treatment Proves Effectiveness 2Health News:New Hair Loss Treatment Proves Effectiveness 3Health News:Long-term cognitive decline in bypass patients not due to surgery 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 3Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 4Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 3Health News:Will lung cancer recur? A genetic test may provide the answer 2
... TCS Symphony orchestrates images and patient ... and information sources in one central ... workflow and improves cost-effectiveness so that ... they do best, helping people., ,Many ...
... illumination with manual intensity control ... light Worldwide voltage and electrical ... unit coo. Easy access for ... will clamp to work station, ...
... Lite positions directly over one,eye permitting ... lens an exclusive feature ,resulting ... optic light that penetrates,deep into a ... swivel mount enables the,surgeon to rotate ...
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
Medicine Products: